亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial

普瑞巴林 医学 安慰剂 麻醉 临床终点 神经病理性疼痛 周围神经病变 神经传导速度 随机对照试验 安慰剂对照研究 糖尿病神经病变 不利影响 内科学 糖尿病 双盲 替代医学 病理 内分泌学
作者
Joseph C. Arezzo,Julio Rosenstock,Linda LaMoreaux,L. Pauer
出处
期刊:BMC Neurology [BioMed Central]
卷期号:8 (1) 被引量:189
标识
DOI:10.1186/1471-2377-8-33
摘要

Recent consensus guidelines recommend pregabalin as a first-tier treatment for painful diabetic peripheral neuropathy (DPN). We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using objective measures of nerve conduction (NC). In this randomized, double-blind, placebo-controlled trial, the primary efficacy measure was endpoint mean pain score (MPS) from daily pain diaries (11-point scale). NC velocity and sensory and motor amplitudes were assessed at baseline, endpoint, and end of follow-up (2 weeks post-treatment). At each timepoint, the median-motor, median-sensory, ulnar-sensory, and peroneal-motor nerves were evaluated. Secondary efficacy measures included weekly MPS and proportion of responders (patients achieving ≥50% reduction in MPS from baseline to endpoint). After 1-weeks' dosage escalation, pregabalin-treated patients received 300 mg BID for 12 weeks. Eighty-two patients received pregabalin and 85 placebo. Mean durations were 10 years for diabetes and ~5 years for painful DPN. Pregabalin-treated patients had lower MPS than controls (mean difference, -1.28; p <.001). For all four nerves, 95% CIs for median differences in amplitude and velocity from baseline to endpoint and baseline to follow-up included 0 (ie, no significant difference vs. placebo). Significant pain improvement among pregabalin-treated patients was evident at week 1 and sustained at every weekly timepoint. More pregabalin-treated patients (49%) than controls (23%) were responders (p <.001). Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN. ClinicalTrials.gov NCT00159679
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
11秒前
19秒前
24秒前
32秒前
NexusExplorer应助科研通管家采纳,获得10
36秒前
所所应助爱笑的毛衣采纳,获得10
39秒前
52秒前
1分钟前
duan完成签到 ,获得积分10
1分钟前
holder完成签到,获得积分10
1分钟前
1分钟前
沐白发布了新的文献求助10
1分钟前
1分钟前
刘宇童发布了新的文献求助10
1分钟前
大模型应助吕易巧采纳,获得10
1分钟前
迷人问兰完成签到,获得积分10
1分钟前
闪闪映易完成签到 ,获得积分10
1分钟前
2分钟前
吕易巧发布了新的文献求助10
2分钟前
吕易巧完成签到,获得积分10
2分钟前
2分钟前
Liiiiiiiiii发布了新的文献求助10
2分钟前
XuchaoD完成签到,获得积分10
2分钟前
2分钟前
今后应助Liiiiiiiiii采纳,获得10
2分钟前
顾矜应助科研通管家采纳,获得10
2分钟前
Akim应助科研通管家采纳,获得10
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
小张完成签到 ,获得积分10
3分钟前
可耐的冰萍完成签到,获得积分10
3分钟前
充电宝应助干净涵梅采纳,获得10
3分钟前
3分钟前
3分钟前
4分钟前
4分钟前
李李发布了新的文献求助10
4分钟前
科研通AI5应助李李采纳,获得10
4分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990049
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270976
什么是DOI,文献DOI怎么找? 1805166
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228